TY - JOUR
T1 - Allergen immunotherapy in MASK-air users in real-life
T2 - Results of a Bayesian mixed-effects model
AU - Sousa-Pinto, Bernardo
AU - Azevedo, Luís Filipe
AU - Sá-Sousa, Ana
AU - Vieira, Rafael José
AU - Amaral, Rita
AU - Klimek, Ludger
AU - Czarlewski, Wienczyslawa
AU - Anto, Josep M.
AU - Bedbrook, Anna
AU - Kvedariene, Violeta
AU - Ventura, Maria Teresa
AU - Ansotegui, Ignacio J.
AU - Bergmann, Karl-Christian
AU - Brussino, Luisa
AU - Canonica, G. Walter
AU - Cardona, Victoria
AU - Carreiro-Martins, Pedro
AU - Casale, Thomas
AU - Cecchi, Lorenzo
AU - Chivato, Tomás
AU - Chu, Derek K.
AU - Cingi, Cemal
AU - Costa, Elisio M.
AU - Cruz, Alvaro A.
AU - de Feo, Giulia
AU - Devillier, Philippe
AU - Fokkens, Wytske J.
AU - Gaga, Mina
AU - Gemicioğlu, Bilun
AU - Haahtela, Tari
AU - Ivancevich, Juan Carlos
AU - Ispayeva, Zhanat
AU - Jutel, Marek
AU - Kuna, Piotr
AU - Kaidashev, Igor
AU - Kraxner, Helga
AU - Larenas-Linnemann, D. sirée E.
AU - Laune, Daniel
AU - Lipworth, Brian
AU - Louis, Renaud
AU - Makris, Michaël
AU - Monti, Riccardo
AU - Morais-Almeida, Mario
AU - Mösges, Ralph
AU - Mullol, Joaquim
AU - Odemyr, Mikaëla
AU - Okamoto, Yoshitaka
AU - Papadopoulos, Nikolaos G.
AU - Patella, Vincenzo
AU - Pham-Thi, Nhân
AU - Regateiro, Frederico S.
AU - Reitsma, Sietze
AU - Rouadi, Philip W.
AU - Samolinski, Boleslaw
AU - Sova, Milan
AU - Todo-Bom, Ana
AU - Taborda-Barata, Luis
AU - Tomazic, Peter Valentin
AU - Toppila-Salmi, Sanna
AU - Sastre, Joaquin
AU - Tsiligianni, Ioanna
AU - Valiulis, Arunas
AU - Wallace, Dana
AU - Waserman, Susan
AU - Yorgancioglu, Arzu
AU - Zidarn, Mihaela
AU - Zuberbier, Torsten
AU - Fonseca, João Almeida
AU - Bousquet, Jean
AU - Pfaar, Oliver
N1 - Funding Information: MASK-air has been supported by Charité Universitätsmedizin Berlin, EU Grants (EU Structural and Development Funds, POLLAR: EIT Health POLLAR, EIT Health Twinning) and educational grants from Mylan-Viatris, ALK, GSK, Novartis and Uriach. Open access funding enabled and organized by Projekt DEAL. Publisher Copyright: © 2022 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.
PY - 2022/3/1
Y1 - 2022/3/1
N2 - Background: Evidence regarding the effectiveness of allergen immunotherapy (AIT) on allergic rhinitis has been provided mostly by randomised controlled trials, with little data from real-life studies. Objective: To compare the reported control of allergic rhinitis symptoms in three groups of users of the MASK-air® app: those receiving sublingual AIT (SLIT), those receiving subcutaneous AIT (SCIT), and those receiving no AIT. Methods: We assessed the MASK-air® data of European users with self-reported grass pollen allergy, comparing the data reported by patients receiving SLIT, SCIT and no AIT. Outcome variables included the daily impact of allergy symptoms globally and on work (measured by visual analogue scales—VASs), and a combined symptom-medication score (CSMS). We applied Bayesian mixed-effects models, with clustering by patient, country and pollen season. Results: We analysed a total of 42,756 days from 1,093 grass allergy patients, including 18,479 days of users under AIT. Compared to no AIT, SCIT was associated with similar VAS levels and CSMS. Compared to no AIT, SLIT-tablet was associated with lower values of VAS global allergy symptoms (average difference = 7.5 units out of 100; 95% credible interval [95%CrI] = −12.1;−2.8), lower VAS Work (average difference = 5.0; 95%CrI = −8.5;−1.5), and a lower CSMS (average difference = 3.7; 95%CrI = −9.3;2.2). When compared to SCIT, SLIT-tablet was associated with lower VAS global allergy symptoms (average difference = 10.2; 95%CrI = −17.2;−2.8), lower VAS Work (average difference = 7.8; 95%CrI = −15.1;0.2), and a lower CSMS (average difference = 9.3; 95%CrI = −18.5;0.2). Conclusion: In patients with grass pollen allergy, SLIT-tablet, when compared to no AIT and to SCIT, is associated with lower reported symptom severity. Future longitudinal studies following internationally-harmonised standards for performing and reporting real-world data in AIT are needed to better understand its ‘real-world’ effectiveness.
AB - Background: Evidence regarding the effectiveness of allergen immunotherapy (AIT) on allergic rhinitis has been provided mostly by randomised controlled trials, with little data from real-life studies. Objective: To compare the reported control of allergic rhinitis symptoms in three groups of users of the MASK-air® app: those receiving sublingual AIT (SLIT), those receiving subcutaneous AIT (SCIT), and those receiving no AIT. Methods: We assessed the MASK-air® data of European users with self-reported grass pollen allergy, comparing the data reported by patients receiving SLIT, SCIT and no AIT. Outcome variables included the daily impact of allergy symptoms globally and on work (measured by visual analogue scales—VASs), and a combined symptom-medication score (CSMS). We applied Bayesian mixed-effects models, with clustering by patient, country and pollen season. Results: We analysed a total of 42,756 days from 1,093 grass allergy patients, including 18,479 days of users under AIT. Compared to no AIT, SCIT was associated with similar VAS levels and CSMS. Compared to no AIT, SLIT-tablet was associated with lower values of VAS global allergy symptoms (average difference = 7.5 units out of 100; 95% credible interval [95%CrI] = −12.1;−2.8), lower VAS Work (average difference = 5.0; 95%CrI = −8.5;−1.5), and a lower CSMS (average difference = 3.7; 95%CrI = −9.3;2.2). When compared to SCIT, SLIT-tablet was associated with lower VAS global allergy symptoms (average difference = 10.2; 95%CrI = −17.2;−2.8), lower VAS Work (average difference = 7.8; 95%CrI = −15.1;0.2), and a lower CSMS (average difference = 9.3; 95%CrI = −18.5;0.2). Conclusion: In patients with grass pollen allergy, SLIT-tablet, when compared to no AIT and to SCIT, is associated with lower reported symptom severity. Future longitudinal studies following internationally-harmonised standards for performing and reporting real-world data in AIT are needed to better understand its ‘real-world’ effectiveness.
KW - allergic rhinitis
KW - immunotherapy
KW - mobile health
KW - patient-reported outcomes
KW - real-life data analysis
UR - http://www.scopus.com/inward/record.url?scp=85127220768&partnerID=8YFLogxK
U2 - https://doi.org/10.1002/clt2.12128
DO - https://doi.org/10.1002/clt2.12128
M3 - Article
C2 - 35344295
SN - 2045-7022
VL - 12
JO - Clinical and Translational Allergy
JF - Clinical and Translational Allergy
IS - 3
M1 - e12128
ER -